Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Only a subset of genetic variants can be examined in genome-wide surveys for genetic risk factors. How can a fixed set of markers account for the entire genome by acting as proxies for neighboring associations?
Contrary to Genentech's claims, turning over all in vitro diagnostics to the US Food and Drug Administration (FDA) is the wrong approach to achieve better clinical validation of tests.
Chambers et al. present an improved method for neural differentiation of human pluripotent stem cells that avoids the use of stromal feeder cells and embryoid bodies. By combining two inhibitors of SMAD signaling, the protocol generates neural cells with an efficiency of >80%.